Page last updated: 2024-09-04

docetaxel anhydrous and Invasiveness, Neoplasm

docetaxel anhydrous has been researched along with Invasiveness, Neoplasm in 207 studies

Research

Studies (207)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	4 (1.93)	18.2507
2000's	63 (30.43)	29.6817
2010's	120 (57.97)	24.3611
2020's	20 (9.66)	2.80

Authors

Authors	Studies
Chen, Y; Guo, W; He, Y; Krimm, I; Li, Y; Liu, M; Mi, D; Pei, H; Shao, T; Wang, P; Wang, X; Yi, Z; Zhang, Y	1
Grobet-Jeandin, E; Pinar, U; Rouprêt, M	1
Black, PC; Roumiguié, M	1
Dewnani, K; diZerega, GS; Kates, M; Lamm, DL; Mansour, AM; Marin, A; Maulhardt, H; Shore, N; Verco, J; Verco, S; Wendt, A	1
Kumar, S; Pareek, T; Parmar, K; Sharma, AP	1
Gellhaus, PT; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL	1
Gellhaus, PT; Martin, AC; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Richards, J; Steinberg, RL	1
Kavoussi, M; Nasrallah, AA; Williams, SB	1
Chevuru, PT; McElree, IM; Mott, SL; O'Donnell, MA; Packiam, VT; Steinberg, RL	1
Araki, M; Kawada, T; Pradere, B; Shariat, SF; Yanagisawa, T	1
O'Donnell, MA; Packiam, VT; Steinberg, RL	1
Abbosh, P; Bell, S; Bukavina, L; Correa, AF; Kutikov, A; Magee, DE; Packiam, VT; Smaldone, M; Uzzo, R	1
Brooks, NA; O'Donnell, MA	1
Bivalacqua, TJ; Brooks, N; Crump, T; Daniels, MJ; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nagaraju, S; Nepple, KG; O'Donnell, MA; Rao, MY; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J	1
Albain, KS; Atkins, JN; Boileau, JF; Borges, VF; Cecchini, RS; Costantino, JP; Crown, JP; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Mamounas, EP; Moore, TD; Paik, S; Polikoff, J; Provencher, L; Rastogi, P; Robidoux, A; Stokoe, C; Swain, SM; Wolmark, N	1
Fujiwara, T; Hashimoto, M; Katsui, K; Maeda, N; Nishizaki, M; Noma, K; Sakurama, K; Shirakawa, Y; Tanabe, S	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Alizadeh Zarei, M; Rafiei Dehbidi, G; Takhshid, MA	1
Chen, H; Jiang, Z; Meng, R; Shi, S; Wang, Y; Wu, S; Xu, L	1
Bivalacqua, TJ; Brooks, N; Crump, T; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J	1
Iwata, S; Kawai, A; Kondo, T; Noguchi, R; Ono, T; Sin, Y; Sugaya, J; Tsuchiya, R; Yoshida, A; Yoshimatsu, Y	1
Chang, PM; Chen, MH; Chu, PY; Lu, HJ; Tai, SK; Wang, LW; Yang, MH	1
Inoue, Y; Maehara, Y; Oki, E; Saeki, H; Tanaka, K; Tokunaga, E; Ueo, H; Yamamoto, H; Yamashita, N	1
Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Singh, AS; Unno, M	1
Beresford, MJ; Jefferies, ER; Sarmah, P; Thompson, AL	1
Alcaraz, J; Gabasa, M; Hilberg, F; Ikemori, R; Reguart, N	1
Alekseev, B; Bamias, A; Bell-McGuinn, KM; Castellano, D; Chi, KN; Cicin, I; Coskun, HS; de Wit, R; Del Muro, XG; Drakaki, A; Fléchon, A; Géczi, L; Hamid, O; Harputluoglu, H; Hegemann, M; Hussain, S; Laestadius, F; Lee, JL; Liepa, AM; Matsubara, N; Necchi, A; Nishiyama, H; Ou, YC; Peer, A; Percent, IJ; Petrylak, DP; Powles, T; Rodriguez-Vida, A; Safina, S; Semenov, A; Sternberg, CN; Su, WP; Tortora, G; Tucci, M; van der Heijden, MS; Walgren, RA; Widau, RC; Yu, EY; Zimmermann, AH	1
Chen, D; Huang, H; Lu, Y; Yang, H	1
Alekseev, B; Beer, TM; Blumenstein, B; Chi, KN; Fizazi, K; Fléchon, A; Gravis, G; Hotte, SJ; Jacobs, CA; Joly, F; Malik, Z; Matveev, V; Saad, F; Stewart, PS	1
Baciuchka, M; Berdah, JF; Beuzeboc, P; Boher, JM; Bousquet, G; Culine, S; Dauba, J; Delva, R; Deplanque, G; Eymard, JC; Ferrero, JM; Fizazi, K; Foulon, S; Gravis, G; Habibian, M; Hasbini, A; Joly, F; Kouri, CE; Krakowski, I; Laguerre, B; Latorzeff, I; Lavaud, P; Legoupil, C; Linassier, C; Machiels, JP; Mourey, L; Oudard, S; Platini, C; Pouessel, D; Priou, F; Ravaud, A; Rolland, F; Soulié, M; Suc, E; Tergemina-Clain, G; Théodore, C; Tubiana-Mathieu, N; Zanetta, S	1
He, MF; Li, CY; Shen, LZ; Tan, AM; Wei, P; Wu, JQ; Zhai, J	1
Boér, K; Dank, M; Dankovics, Z; Küronya, Z; Lahm, E; Maráz, A; Petrányi, Á; Révész, J; Ruzsa, Á; Szûcs, M; Valikovics, A; Vas, M	1
Chen, C; Chen, Y; Jiang, X; Li, S; Shi, F; Wang, X; Xiong, H; Yan, T; Zhang, W; Zhu, Y	1
Ci, X; Clermont, PL; Collins, CC; Dong, X; Gout, PW; Hao, J; Lin, D; Qu, S; Wang, Y; Wu, R; Xue, H	1
Doki, Y; Gakuhara, A; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Tanaka, K; Yamasaki, M	1
Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Odagiri, K; Takahashi, T; Tanaka, K; Yamazaki, M	1
Ding, XZ; Gao, SG; He, Y; Hu, XC; Kong, DJ; Li, XC; Li, Y; Lin, TY; Wang, XS; Yang, JQ; Zhang, L; Zhao, MQ	1
Hameed, I; Lin, JZ; Ren, ZY; Xu, Z; Yu, Y; Zhu, JG	1
Aksoy, S; Aktas, BY; Alacacioglu, A; Aliyev, A; Artac, M; Basaran, G; Beypinar, I; Bilen, E; Bilici, A; Cabuk, D; Cetin, B; Cicin, I; Cil, T; Degirmencioglu, S; Demir, A; Demir, H; Demirci, U; Er, O; Erdur, E; Eren, T; Erturk, I; Esin, E; Evrensel, T; Gumusay, O; Haksoyler, V; Harputluoglu, H; Imamoglu, I; Kaplan, MA; Karaagac, M; Karadurmus, N; Kocer, M; Korkmaz, T; Kostek, O; Oksuzoglu, B; Olgun, P; Oyan, B; Ozdemir, O; Paydas, S; Pilanci, KN; Sakalar, T; Sakin, A; Seker, M; Sumbul, AT; Tanrikulu, E; Urun, Y; Yetisir, E; Yildirim, N; Yilmaz, H; Yumuk, PF	1
Bengala, C; Bisagni, G; Brandes, AA; Cagossi, K; Gianni, L; Gori, S; Iannacone, C; Montemurro, F; Morandi, P; Stell, A; Zamagni, C; Zambetti, M	1
Cao, S; Han, B; Teng, J; Xu, J; Zhong, H	1
Lü, Z; Wang, X; Wu, H; Xu, Q; Zhu, Q	1
He, W; Li, L; Li, Z; Liu, T; Ren, Y; Wang, J; Yan, M; Zhang, Y	1
Chuu, CP; Hour, TC; Lai, CJ; Liao, WY; Lin, CY; Wang, HD	1
Cheng, WC; Chiu, FY; Fang, SH; Hsieh, KL; Huang, KH; Huang, MY; Huang, SP; Li, CY; Lin, IL; Liu, PL; Su, CC; Yeh, HC	1
Chen, Q; Wang, X; Wei, KJ; Yu, YC	1
Akiyama, Y; Baba, S; Chiba, T; Endo, F; Iwaya, T; Kimura, T; Kimura, Y; Koeda, K; Mizuno, M; Nikai, H; Nitta, H; Otsuka, K; Sasaki, A; Takahara, T	1
Agarwal, A; Aljumaily, R; Covic, L; Kaimal, R; Kim, YB; Kuliopulos, A; Pradhan, RV; Sharifi, S; Tressel, SL; Zarwan, C	1
Batra, SK; Johansson, SL; Mimeault, M	1
Angspatt, A; Sriussadaporn, S	1
Fujiwara, H; Furukawa, T; Furukita, Y; Goto, M; Ikeda, M; Morimoto, M; Nishino, T; Seike, J; Takechi, H; Tangoku, A; Yamamoto, Y	1
Du, G; Li, L; Li, X; Xiao, W; Yang, H; Yu, M; Zhang, Z	1
Atkins, JN; Azar, CA; Biggs, DD; Brufsky, AM; Costantino, JP; Donnellan, PP; Fehrenbacher, L; Geyer, CE; Levine, EA; Mamounas, EP; Northfelt, DW; Paik, S; Polikoff, JA; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Tang, G; Wolmark, N; Zapas, JL	1
Fajdiga, I; Gale, N; Grašič Kuhar, C; Jančar, B; Kadivec, M; Karner, K; Kocjan, BJ; Poljak, M; Strojan, P; Zakotnik, B; Žumer, B	1
Lin, J; Pan, W; Shi, H; Wu, H; Yu, H; Zhu, J	1
Antonarakis, ES; Bassi, S; Carducci, MA; Eisenberger, MA; Schweizer, MT; Wang, H; Zhou, XC	1
Petrylak, DP	1
Ban, X; Cai, Z; Cao, TT; Chen, J; Fu, L; Guan, XY; Huang, P; Li, JB; Li, Y; Qian, C; Qin, Y; Xie, D; Zeng, TT; Zeng, ZL; Zhou, J	1
Barron, SL; Batten, K; Cornelius, C; Fasciani, G; Jia, G; Shay, JW; Singel, SM; Wright, WE	1
Hayashi, N; Kajiura, Y; Matsuda, N; Nakamura, S; Ohde, S; Suzuki, K; Tsunoda, H; Yagata, H; Yamauchi, H; Yoshida, A	1
de Riese, W; Filleur, S; Hirsch, J; Lopez, J; Martinez-Marin, D; Miller, B; Nelius, T; Rinard, K	1
Brock, MV; Guo, M; Herman, JG; Lu, Y; Wu, K; Yan, W; Yang, Y; Zhang, Z; Zhou, Y	1
Argiris, A; Fu, P; Galanopoulos, N; Gibson, M; Lavertu, P; Machtay, M; Rezaee, R; Savvides, P; Wasman, J; Yao, M; Zender, C	1
Ades, S; Alcindor, T; Aloraini, A; Asselah, J; Brisson, S; David, M; Ferri, L; Frechette, D; Sudarshan, M; Thirlwell, M; van Huyse, M	1
Benzonana, LL; Bevan, C; Brown, R; Huang, H; Ma, D; Perry, NJ; Watts, HR; Zhao, H	1
Ishibashi, Y; Ito, Y; Omori, K; Wakabayashi, K	1
Bhosle, S; Brown, SG; Chaudhary, J; Hunt, A; Knowell, AE; Patel, D	1
Feng, J; Gu, J; Huang, J; Ni, S; Wang, H; Xu, L; Zhang, S; Zhang, W; Zhu, H	1
Bilici, A; Demir, N; Dikilitas, M; Oven Ustaalioglu, BB; Selcukbiricik, F; Yildiz, O	1
Amir, E; de Wit, R; Eisenberger, MA; Mercier, F; Rosenthal, M; Sonpavde, G; Tannock, IF; Templeton, AJ; Tombal, B; van Soest, RJ; Vera-Badillo, FE	1
Chen, J; Dong, L; Gong, J; Jia, H; Kong, Y; Li, J; Lin, H; Liu, C; Luo, M; Ma, Y; Su, R; Wang, F; Wang, Y; You, L; Yu, J; Zhang, J; Zhang, Z	1
Baciuchka, M; Berdah, JF; Beuzeboc, P; Chinet-Charrot, P; Cojean-Zelek, I; Culine, S; Davin, JL; Delva, R; Deplanque, G; Faivre, L; Ferrero, JM; Fizazi, K; Fléchon, A; Gravis, G; Habibian, M; Houede, N; Krakowski, I; Labourey, JL; Lagrange, JL; Laguerre, B; Laplanche, A; Legouffe, E; Lesaunier, F; Linassier, C; Martin, AL; Mourey, L; Oudard, S; Priou, F; Ravaud, A; Rolland, F; Theodore, C	1
Bansal, N; Bertino, JR; DiPaola, RS; Mishra, PJ; Stein, M	1
Yaqub, F	1
Fizazi, K; Saad, F	1
Cao, HX; Chen, W; Ji, H; Jiang, LH; Li, J; Ma, R; Mao, L; Sun, DW; Tang, JH; Wang, J; Wu, JZ; Wu, Y; Zhang, HD; Zhang, J	1
Rexer, H	1
Chang, DT; Dudley, SA; Durkee, BY; Gibbs, IC; Goldhaber-Fiebert, JD; Horst, KC; King, MT; Pollom, EL; Qian, Y; Shaffer, JL	1
Capanu, M; Henderson, C; Janjigian, YY; Kelsen, DP; Kemeny, M; Krishnamurthi, S; Mehrotra, B; Ocean, A; Ritch, P; Shah, MA; Shibata, S; Stoller, R; Su, YB	1
Hayashi, T; Horii, N; Inoue, H; Kimura, J; Kunisaki, C; Maezawa, Y; Makino, H; Masuda, M; Ohnishi, H; Ohshima, T; Rino, Y; Suzuki, Y; Takagawa, R; Tsuburaya, A; Yamamoto, J	1
Cai, Y; Chen, M; Fang, X; He, C; Li, P; Wang, Y; Xiao, F	1
Gehrig, PA; Kim, KH; Milam, B; Palisoul, M; Raker, C; Robison, K; Roque, DR; Taylor, KN; Wysham, WZ	1
Clauditz, T; Knecht, R; Laban, S; Muenscher, A; Schafhausen, P; Tribius, S; Veldhoen, S; Zielinski, V	1
Hah, JH; Han, DH; Heo, DS; Keam, B; Kim, DW; Kim, DY; Kim, TM; Kwon, TK; Lee, SH; Ock, CY; Rhee, CS; Sung, MW; Won, TB; Wu, HG	1
Alpert, Y; Bruchim, I; Fishman, A; Piura, E; Sade, D; Weeg, N	1
Ameri, A; Khoshbakht Ahmadi, H; Mortazavi, N; Novin, K	1
Huang, CQ; Ji, ZH; Li, Y; Peng, KW; Sun, JH; Wu, HT; Yang, XJ; Zhang, Q	1
Azfer, A; Jamil, NS; Salter, DM; Worrell, H	1
Ai, J; Hou, M; Li, W; Liu, H; Tan, G; Xie, Z; Zeng, R	1
Chen, J; Chen, L; Chu, X; Song, H; Wang, R; Zhang, K	1
Aretin, MB; Fuchs, H; Fuereder, T; Grah, A; Kornek, G; Pammer, J; Posch, D	1
Dowlati, A; Fu, P; Pennell, NA; Sharma, N; Yi, Q	1
Ishikawa, A; Matsubara, A; Oue, N; Sakamoto, N; Sekino, Y; Sentani, K; Shigematsu, Y; Teishima, J; Yasui, W	1
Batra, SK; Chen, HT; Hsieh, KC; Ingersoll, MA; Kao, CL; Lin, MF; Martinez, O; Miller, DR; Simha, MV; Wakefield, CB	1
Cookson, MS; Ritch, CR	1
Bachelder, RE; Bowie, M; Cook, M; de Ridder, G; Groth, J; Kennedy, M; Kilibarda, K; Li, S; Lyes, M; Marcom, PK; McDonnell, DP; Nelson, ER; Parilla-Castellar, E; Payne, S; Peterson, BL; Pizzo, SV	1
Chen, D; Ding, L; Li, J; Luo, LJ; Ma, R; Tang, JH; Wang, DD; Wu, JZ; Yang, F; Yang, SJ; Zhang, L	1
Baselga, J; Clark, E; Eng-Wong, J; Fox, S; Kiermaier, A; Loi, S; Luen, SJ; Michiels, S; Salgado, R; Savas, P; Swain, SM	1
Abdelhay, ESFW; Assumpção, PP; Burbano, RR; de Souza, MC; Demachki, S; Leal, MF; Moreira-Nunes, CA; Pereira, CBL; Smith, MC; Tanaka, AMDS	1
Alunni-Fabbroni, M; Andergassen, U; Camara, O; de Gregorio, N; Decker, T; Fasching, PA; Fehm, TN; Friedl, TWP; Heinrich, G; Jaeger, B; Janni, W; Mahner, S; Ober, A; Pantel, K; Rack, BK; Schneeweiss, A; Schochter, F; Schramm, A; Trapp, E	1
Bagante, F; Connolly, R; Pawlik, TM; Spolverato, G; Vitale, A	1
Hu, S; Jiang, Y; Sun, Y; Xue, L; Xue, X; Yang, L; Yue, J; Zhu, Y	1
Castro, M; Corvacho, E; Costa, JG; Fernandes, AS; Guerreiro, PS; Miranda, JP; Oliveira, NG; Saraiva, N	1
Chi, KN; Chin, JL; Gleave, ME; Klotz, L; Saad, F; Winquist, E	1
Beuzeboc, P; Bompas, E; Ferrero, JM; Fizazi, K; Fléchon, A; Gravis, G; Italiano, A; Joly, F; Ortholan, C; Oudard, S; Pouessel, D	1
Agarwal, A; Azabdaftari, G; Covic, L; Kaneider, NC; Kuliopulos, A; Lazarides, K; Sevigny, LM; Sharifi, S	1
Gomi, K; Hayasaka, M; Koizumi, T; Kubo, K; Nakamura, M; Shikama, N; Tsushima, K; Yasuo, M	1
Asai, K; Hirata, K; Ichimaru, Y; Kimura, T; Kodama, T; Kudoh, S; Kyoh, S; Mitsuoka, S; Tochino, Y; Yana, T; Yoshimura, N	1
Barlow, LJ; Benson, MC; McKiernan, JM	2
Balbi, C; Barboro, P; Benelli, R; Ferrari, N; Monteghirfo, S	1
Chang, PN; Lee, DT; Ling, MT; Wong, YC; Yap, WN; Yap, YL	1
Barlow, L; Benson, M; McKiernan, J; Sawczuk, I	1
Chikazawa, N; Iijima, H; Ikebe, M; Jo, E; Kameda, C; Katano, M; Morisaki, T; Nagai, S; Nakamura, M; Sato, N; Sekine, F; Shoda, M; Suzuki, H; Tanaka, H; Tasaka, T; Wada, J; Yamasaki, A	1
Choudhury, A; Clark, JI; Eisner, RM; Emami, B; Hofmeister, C; Lathers, D; Lau, A; Norton, J; Petruzzelli, G; Thomas, S; Young, MR	1
Dai, B; Mao, HR; Shen, YJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y	1
Al Hasan, SA; Cher, ML; Dickow, B; Eliason, J; Heilbrun, LK; Marur, S; Smith, DW; Vaishampayan, UN	1
Alanko, T; Asola, R; Bono, P; Hahka-Kemppinen, M; Huuhtanen, R; Joensuu, H; Kellokumpu-Lehtinen, P; Kokko, R; Leinonen, M; Pyrhönen, S; Sailas, L; Sunela, K; Turpeenniemi-Hujanen, T; Utriainen, M; Wigren, T	1
Bond, VK; Im, DD; Matsuo, K; Rosenshein, NB	1
Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C	1
Hirata, K; Kato, J; Kida, M; Kobune, M; Miyanishi, K; Niitsu, Y; Ohnuma, H; Ohta, H; Okubo, S; Sagawa, T; Sato, T; Sato, Y; Shintani, N; Takahashi, Y; Takayama, T; Takimoto, R; Tanaka, S; Yamaguchi, K	1
Bibeau, F; Bleuse, JP; Colombo, PE; Gourgou-Bourgade, S; Gutowski, M; Jacot, W; Kramar, A; Romieu, G	1
Habermehl, GK; Iczkowski, KA; Tang, Y; Yang, K	1
Andreoni, B; Biffi, R; Bonomo, G; Chiappa, A; Crosta, C; Fazio, N; Fiori, G; Huber, O; Luca, F; Orsi, F; Roth, A; Schuller, JC; Zampino, MG	1
Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Mimeault, M	1
Kimura, T; Kogashiwa, Y; Kohno, N; Sakurai, H	1
Antonini, N; Linn, SC; Loo, CE; Oldenburg, HS; Rodenhuis, S; Russell, NS; Rutgers, EJ; Straver, ME; Vrancken Peeters, MT; Wesseling, J	1
Bertheau, P; Brain, E; Delaloge, S; Espié, M; Guinebretière, JM; Marty, M; Mathieu, MC; Pierga, JY; Savignoni, A; Sigal-Zafrani, B; Spielmann, M	1
Jotoku, H; Taguchi, K; Tamura, M; Watanabe, K; Yamamoto, M	1
Kito, F; Kunisaki, C; Matsuda, S; Mochizuki, Y; Takahashi, M; Watanabe, J; Yabuno, T	1
Azria, D; Delpero, JR; Giovannini, M; Moureau-Zabotto, L; Moutardier, V; Rouanet, P; Turrini, O; Viret, F; Ychou, M	1
Ah-See, ML; Beresford, MJ; Collins, DJ; d'Arcy, JA; Li, SP; Makris, A; Padhani, AR; Stirling, JJ; Taylor, NJ	1
Allory, Y; Buttyan, R; Coppolani, E; Culine, S; de la Taille, A; Kheuang, L; Maillé, P; Nicolaiew, N; Paule, B; Ploussard, G; Salomon, L; Sirab, N; Soyeux, P; Terry, S; Vacherot, F	1
Chang, SY; Chang, YC; Chu, PY; Hsieh, SL; Li, WY; Tai, SK; Tsai, TL; Wang, YF; Yang, MH	1
Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kawasaki, Y; Kurokawa, T; Nagahama, T; Tei, S; Watayou, Y	1
Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kawaguchi, T; Kokuba, Y; Komatsu, S; Konishi, H; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T; Yoshikawa, T	1
Baker, JH; Brooks, DE; Burt, HM; Gleave, ME; Liggins, R; Manisali, I; Matsui, Y; Minchinton, AI; Mugabe, C; So, AI	1
Corrado, G; di Stefano, A; Ferrandina, G; Lucidi, A; Margaritora, S; Piraino, A; Salutari, V; Scambia, G	1
Androulakis, N; Boukovinas, I; Constantinides, CA; Georgoulias, V; Karampeazis, A; Kentepozidis, N; Kostakopoulos, A; Kotsakis, A; Markos, V; Mavroudis, D; Papakotoulas, P; Polyzos, A; Samonis, G; Vardakis, N; Ziras, N	1
Gao, F; Luo, J; Sun, X; Sun, Z; Wang, H; Zhao, X; Zhong, B	1
Altevogt, P; Benner, A; Biakhov, MY; Bottini, A; Bretz, N; Burwinkel, B; Friedrichs, K; Hug, S; Keller, S; Khailenko, VA; Kristiansen, G; Lichter, P; Manikhas, GM; Marmé, F; Moldenhauer, G; Ruiz, A; Rupp, AK; Rupp, C; Sánchez-Rovira, P; Santoro, A; Schneeweiss, A; Segui, MA; Sinn, P; Sohn, C; Villena, C; Walter, A; Wang, X; Werft, W	1
Avisar, E; Deutsch, YE; Diaz-Montero, CM; Garret-Mayer, E; Glück, S; Hurley, J; Jorda, M; Koniaris, LG; Montero, AJ; Pegram, MD; Rumboldt, T; Schuhwerk, K; Seo, P; Silva, O; Slingerland, J; Welsh, C; Yasir, S	1
Bianchi, G; de la Haba-Rodriguez, J; Gianni, L; Im, SA; Im, YH; Liu, MC; Lluch, A; Morandi, P; Pedrini, JL; Pienkowski, T; Poirier, B; Ratnayake, J; Roman, L; Ross, G; Semiglazov, V; Srimuninnimit, V; Staroslawska, E; Szado, T; Tseng, LM; Valagussa, P	1
Dok, Y; Hamakawa, T; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M	1
Adler, AI; George, E; Jilani, A	1
Liu, J; Liu, ZL; Wang, H; Wang, ZX	1
Baldotto, C; Bennouna, J; Ciuleanu, TE; Goksel, T; Gorbunova, V; Le-Guennec, S; Miller, V; Novello, S; Ozguroglu, M; Ramlau, R; Rey, A; Scagliotti, G; Shepherd, FA; Thatcher, N	1
Agarwal, A; Cooley, TP; Logeswaran, P; Mehta, A; Subramaniam, RM	1
Asakawa, T; Furusaka, T; Ikeda, M; Matsuda, H; Tanaka, A	1
Culig, Z; Erb, HH; Heidegger, I; Hoefer, J; Klocker, H; Neuwirt, H; Oh, SJ; Puhr, M; Schäfer, G	1
Abe, Y; Kusunose, H; Muto, M; Nagura, H; Namima, T; Satake, Y; Tagami, K; Takeuchi, A; Tanda, S	1
Ai, ZH; Guo, JZ; Liu, WC; Wang, Y; Wen, L; Zhao, SH	1
Chen, L; Chen, Y; Ren, J; Song, H; Wang, R	1
Chow, LW; Glück, S; Im, SA; Lee, MH; Ng, TY; Toi, M; Tung, SY; Yip, AY	1
Baron, R; Binder, A; Hilpert, F; Pfisterer, J; Schattschneider, J; Wasner, G	1
Asaumi, Y; Hara, T; Hirano, M; Kikkawa, H; Kikuchi, T; Murakami, N; Nozawa, H; Takizawa, M; Uno, Y	1
Anderson, SJ; Brown, A; Desai, AM; Kardinal, CG; Lembersky, BC; Mamounas, EP; Scholnik, AP; Smith, RE	1
Bernard-Marty, C; Bissery, MC; Cardoso, F; Di Leo, A; Dumontet, C; Fellous, A; Gancberg, D; Larsimont, D; Paesmans, M; Piccart, MJ; Treilleux, I	1
Achard, JL; Amat, S; Body, G; Bougnoux, P; Chollet, P; Curé, H; Dauplat, J; Fétissof, F; Kwiatkowski, F; Penault-Llorca, F	1
Scagliotti, GV; Turrisi, AT	1
Guillén Grima, F; Peñuelas Sánchez, I; Sánchez Lerma, B	1
Van Cutsem, E	1
Rigas, JR	1
Crown, J; O'Leary, M; Ooi, WS	1
Bamias, A; Deliveliotis, C; Dimopoulos, MA; Gika, D; Karayiannis, A; Pantazopoulos, D; Varkarakis, I; Zervas, I	1
Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U	1
Griffith, KA; Kleer, CG; Pu, RT; Schott, AF; Sturtz, DE	1
Andrieu, JM; Banu, A; Banu, E; Beuzeboc, P; Coscas, Y; Dourthe, LM; Guinet, F; Hardy-Bessard, AC; Linassier, C; Oudard, S; Poupon, MF; Scotté, F; Voog, E	1
Carducci, MA	1
Bartsch, R; Gnant, MF; Hussian, D; Jakesz, R; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC	1
Chisholm, GB; Cruz, AB; Kahlenberg, MS; Learn, PA; McNutt, M; Pollock, BH; Rousseau, DL; Sharkey, FE; Yeh, IT	1
Deguchi, Y; Doi, H; Higuchi, A; Komai, Y; Sakai, M; Shioya, M; Takenaka, K	1
Erban, J; Gradishar, WJ; Jahanzeb, M; Limentani, SA; Olsen, SR; Swain, SM; Tsai, KT; Wedam, SB	1
Bosch, CA; Hannemann, J; Loo, C; Oosterkamp, HM; Rodenhuis, S; Rutgers, EJ; van de Vijver, MJ; Velds, A; Wessels, LF	1
Alexopoulos, A; Apostolikas, N; Ardavanis, A; Karamouzis, MV; Papadopoulou, A; Rigatos, G	1
Hitzl, W; Peintinger, F; Prokop, E; Reitsamer, R	1
Burdick, RK; Cunningham, SC; Cusnir, M; Moesinger, R; Van Echo, DA	1
Kato, K; Kim, SJ; Miyoshi, Y; Nakamura, H; Noguchi, S; Taguchi, T; Tamaki, Y; Yodoi, J	1
Aggarwal, BB; Ajani, JA; Chao, KS; Ensor, J; Hittelman, WN; Izzo, JG; Lee, JH; Liao, Z; Luthra, R; Malhotra, U; Swisher, SG; Wu, TT	1
Besova, NS; Borisova, TA; Gorbunova, VA; Markovich, AA; Orel, NF; Zaguzina, NN	1
Chow, LW; Yip, AY	1
Azuma, K; Hashine, K; Miura, N; Numata, K; Sumiyoshi, Y	1
Cavaglione, G; Chamorey, E; Dides, S; Ferrero, JM; Foa, C; Kaphan, R; Lesbats, G; Nouyrigat, P; Oudard, S	1
Angellier, E; Berdah, JF; Buyse, M; Fabbro, M; Greget, S; Herait, P; Jehl, V; Laplaige, P; Piedbois, P; Priou, F; Serin, D; Teissier, E; Valenza, B	1
Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H	1
Bernini, M; Cordiano, C; de Manzoni, G; Giacopuzzi, S; Grandinetti, A; Minicozzi, AM; Pasini, F; Pedrazzani, C	1
Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Vankatraman, G	1
Angelucci, D; Carella, C; Cianchetti, E; De Tursi, M; Ficorella, C; Grassadonia, A; Grossi, S; Iacobelli, S; Natoli, C; Ricevuto, E; Rispoli, AI; Tinari, N; Zilli, M	1
Chansky, K; Chapman, RA; Crowley, JJ; Doroshow, JH; Gandara, DR; Goodwin, JW; Gross, HM; Hesketh, PJ; Lau, DH; Moinpour, CM	1
Bedano, PM; Hanna, NH	1
Hasegawa, Y; Inoue, A; Ishida, T; Ishimoto, O; Koinumaru, S; Miki, H; Munakata, M; Nukiwa, T; Saijo, Y; Sugawara, S; Suzuki, T	1
Chansky, K; Chapman, RA; Crowley, JJ; Dowlati, A; Gandara, DR; Graham, P; Hesketh, PJ; Lilenbaum, RC	1
Burks, T; Chaudhary, UB; Curry, N; Sawhney, R	1
Goh, BC; Lee, HS; Lee, SC; Soo, R; Sukri, N; Tham, LS; Wang, LZ; Wong, CI; Yong, WP	1
Date, H; Kiura, K; Mori, H; Toyooka, S	1
McKeage, MJ	1
Hussain, M; Vaishampayan, U	1
Andrieu, JM; Banu, A; Banu, E; Ebenezer, C; Levy, E; Marsan, S; Medioni, J; Oudard, S; Scotté, F; Tourani, JM	1
Andreetta, C; Cardellino, GG; Crivellari, D; Damante, G; Di Loreto, C; Lombardi, D; Magri, MD; Mansutti, M; Minisini, AM; Perin, T; Puglisi, F; Russo, S; Veronesi, A	1
Clynes, M; Henry, M; Keenan, J; Meleady, P; Murphy, L	1
Azli, N; Chevallier, B; Dieras, V; Fumoleau, P; Kerbrat, P; Krakowski, I; Lentz, MA; Misset, JL; Murawsky, M; Pouillart, P; Riva, A; Roche, H	1
Béhar, A; Brun, MD; Chauvin, FF; Feuilhade de Chauvin, F; Hille, D; Maurel, A; Oulid-Aissa, D; Pujade-Lauraine, E	1
Antoine, EC; Khayat, D	1
Boissier, S; Clezardin, P; Delmas, PD; Magnetto, S	1
Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y	1
Ando, A; Miyoshi, Y; Noguchi, S; Taguchi, T; Takamura, Y; Tamaki, Y	1
Appert, H; Howard, J; Iwamura, T; Liu, B; Staren, E	1

Reviews

20 review(s) available for docetaxel anhydrous and Invasiveness, Neoplasm

Article	Year
Sequential intravesical gemcitabine and docetaxel therapy in patients with nonmuscle invasive bladder cancer: a systematic review and meta-analysis. Current opinion in urology, 2023, 05-01, Volume: 33, Issue:3 Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms	2023
Combination Intravesical Therapy. The Urologic clinics of North America, 2020, Volume: 47, Issue:1 Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms	2020
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world. BJU international, 2017, Volume: 120, Issue:6 Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Physical Fitness; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome	2017
Primary angiosarcoma of the breast: a case report and review of the literature. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2013, Volume: 96, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Developing Countries; Docetaxel; Female; Gemcitabine; Hemangiosarcoma; Humans; Lymph Node Excision; Magnetic Resonance Imaging; Mammaplasty; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Surgical Flaps; Taxoids; Thailand	2013
Challenges in treating advanced disease. The American journal of managed care, 2013, Volume: 19, Issue:18 Suppl Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Invasiveness; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome	2013
Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer. Urology, 2015, Volume: 86, Issue:5 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Secondary Prevention; Survival Analysis; Taxoids; Treatment Outcome	2015
Cucurbitacins: A Systematic Review of the Phytochemistry and Anticancer Activity. The American journal of Chinese medicine, 2015, Volume: 43, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Cucurbitacins; Docetaxel; Drug Therapy, Combination; Humans; Methotrexate; Molecular Conformation; Neoplasm Invasiveness; Neoplasms; Phytotherapy; Signal Transduction; Structure-Activity Relationship; Taxoids	2015
Management of sinonasal undifferentiated carcinoma with intracerebral invasion: Clinical experience at a single institution and review of the literature. Ear, nose, & throat journal, 2016, Volume: 95, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Magnetic Resonance Imaging; Male; Maxillary Sinus Neoplasms; Neoplasm Invasiveness; Otorhinolaryngologic Surgical Procedures; Taxoids; Tomography, X-Ray Computed	2016
Advances in the management of castration resistant prostate cancer. BMJ (Clinical research ed.), 2016, Oct-17, Volume: 355 Topics: Aged; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Management; Docetaxel; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2016
[Successful chemotherapy with a docetaxel regimen for primary signet-ring cell carcinoma of the urinary bladder-a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Neoplasm Invasiveness; Taxoids; Tomography, X-Ray Computed; Urinary Bladder Neoplasms	2012
Docetaxel-based combined-modality chemoradiotherapy for locally advanced non-small cell lung cancer. The oncologist, 2003, Volume: 8, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Education, Medical, Continuing; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pneumonectomy; Prognosis; Radiation Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2003
[Docetaxel in combination with cisplatin for first-line treatment of locally advanced or metastatic non-small cell lung cancer: meta-analysis of randomized and controlled clinical trials]. Medicina clinica, 2004, Mar-06, Volume: 122, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome	2004
The treatment of advanced gastric cancer: new findings on the activity of the taxanes. The oncologist, 2004, Volume: 9 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2004
Taxane-platinum combinations in advanced non-small cell lung cancer: a review. The oncologist, 2004, Volume: 9 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2004
Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. The oncologist, 2004, Volume: 9 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2004
Salvage therapy in patients with advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids	2006
The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Invasiveness; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Xanthones	2008
Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert review of anticancer therapy, 2008, Volume: 8, Issue:2 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Immunotherapy; Infusions, Intravenous; Male; Neoplasm Invasiveness; Neoplasm Staging; Palliative Care; Prednisone; Prognosis; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Time Factors	2008
[The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 1998, Volume: 2 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Taxoids; Urinary Bladder Neoplasms	1998

Trials

63 trial(s) available for docetaxel anhydrous and Invasiveness, Neoplasm

Article	Year
Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer. The Journal of urology, 2022, Volume: 208, Issue:4 Topics: Administration, Intravesical; BCG Vaccine; Docetaxel; Humans; Immune Checkpoint Inhibitors; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Tumor Microenvironment; Urinary Bladder Neoplasms	2022
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 02-10, Volume: 38, Issue:5 Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Neoplasm Invasiveness; Receptor, ErbB-2; Risk Factors; Trastuzumab	2020
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study. Head & neck, 2017, Volume: 39, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome	2017
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet (London, England), 2017, Nov-18, Volume: 390, Issue:10109 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Internationality; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Ramucirumab; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms	2017
Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer. Medicine, 2017, Volume: 96, Issue:41 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemoradiotherapy; Cyclophosphamide; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Mastectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Taxoids; Treatment Outcome	2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph The Lancet. Oncology, 2017, Volume: 18, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Internationality; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prednisone; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Thionucleotides; Tomography, X-Ray Computed; Treatment Outcome	2017
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. European urology, 2018, Volume: 73, Issue:5 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Belgium; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; France; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Treatment Outcome	2018
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. European journal of cancer (Oxford, England : 1990), 2018, Volume: 105 Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Genes, erbB-2; Heart Diseases; Humans; Injections, Subcutaneous; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Stroke Volume; Trastuzumab	2018
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Sep-10, Volume: 31, Issue:26 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Taxoids	2013
Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. Head & neck, 2015, Volume: 37, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate; Taxoids; Treatment Outcome	2015
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Follow-Up Studies; Humans; International Agencies; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neutrophils; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids	2015
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. The Lancet. Oncology, 2015, Volume: 16, Issue:7 Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; France; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2015
Nivolumab for squamous-cell non-small-cell lung cancer. The Lancet. Oncology, 2015, Volume: 16, Issue:7 Topics: Antibodies, Monoclonal; Baltimore; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Invasiveness; Nivolumab; Prognosis; Proportional Hazards Models; Survival Analysis; Taxoids	2015
[Study on therapy of metastasized or locally advanced urothelial cancer: A phase III randomized clinical trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel or vinflunine in subjects with recurrent or progressive metastatic urothelial cancer (Ke Der Urologe. Ausg. A, 2015, Volume: 54, Issue:9 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Docetaxel; Europe; Germany; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; United States; Vinblastine	2015
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, Mar-20, Volume: 34, Issue:9 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Decision Support Techniques; Docetaxel; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Invasiveness; Receptor, ErbB-2; Taxoids; Trastuzumab; United States	2016
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-20, Volume: 33, Issue:33 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Risk Assessment; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; United States	2015
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cohort Studies; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids	2016
Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer. Scientific reports, 2016, 09-06, Volume: 6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Taxoids	2016
Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer. Reviews on recent clinical trials, 2017, Volume: 12, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Proportional Hazards Models; Quinazolines; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2017
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. The Lancet. Oncology, 2017, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; Double-Blind Method; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Taxoids; Trastuzumab; Young Adult	2017
Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer. Clinical breast cancer, 2017, Volume: 17, Issue:4 Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Prevalence; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Young Adult	2017
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. The Journal of urology, 2008, Volume: 180, Issue:2 Topics: Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Biopsy, Needle; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2008
Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Radiation Dosage; Taxoids; Thorax	2009
Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:3 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2009
A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. BJU international, 2009, Volume: 104, Issue:8 Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms	2009
Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer. American journal of clinical oncology, 2009, Volume: 32, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Prospective Studies; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2009
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer. The Journal of urology, 2009, Volume: 182, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Prognosis; Prostatectomy; Prostatic Neoplasms; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome	2009
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome	2010
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult	2009
Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:4 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur; Treatment Outcome	2010
Phase II trial of dose dense docetaxel followed by FEC100 as neoadjuvant chemotherapy in patients with operable breast cancer. American journal of clinical oncology, 2010, Volume: 33, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome	2010
Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World journal of gastroenterology, 2010, Feb-21, Volume: 16, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Endosonography; Europe; Feasibility Studies; Female; Fluorouracil; Gastrectomy; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Radionuclide Imaging; Stomach Neoplasms; Taxoids; Time Factors; Tomography, Spiral Computed; Treatment Outcome	2010
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast cancer research and treatment, 2010, Volume: 122, Issue:2 Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; France; Humans; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids; Therapeutics; Time Factors; Trastuzumab	2010
Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2010, Volume: 36, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Confidence Intervals; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2010
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscles; Nausea; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Taxoids; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms	2012
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. Breast cancer research and treatment, 2012, Volume: 132, Issue:3 Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Genotype; Glutamates; Guanine; Humans; Leukocyte Common Antigens; Lymphocytes; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pemetrexed; Polymorphism, Genetic; Sequence Analysis, DNA; Statistics, Nonparametric; Taxoids; Treatment Outcome	2012
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast cancer research and treatment, 2012, Volume: 132, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Combinations; Female; Glutathione Disulfide; Humans; Immunity, Cellular; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Receptor, ErbB-2; Taxoids; Treatment Outcome; Young Adult	2012
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. The Lancet. Oncology, 2012, Volume: 13, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Brazil; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Docetaxel; Europe; Female; Humans; Inflammation; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Receptor, ErbB-2; Taxoids; Time Factors; Trastuzumab; Treatment Outcome; Young Adult	2012
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-10, Volume: 30, Issue:29 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Prognosis; Proportional Hazards Models; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2012
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Celecoxib; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Phenobarbital; Prospective Studies; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Taxoids	2013
Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Clinical breast cancer, 2002, Volume: 3, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cause of Death; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome	2002
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. British journal of cancer, 2003, May-06, Volume: 88, Issue:9 Topics: Antineoplastic Agents, Phytogenic; Blood Cell Count; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Methylprednisolone; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Recurrence; Survival Analysis; Taxoids; Treatment Outcome	2003
Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis. The American journal of surgical pathology, 2005, Volume: 29, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Necrosis; Neoadjuvant Therapy; Neoplasm Invasiveness; Prognosis; Prospective Studies; Taxoids; Treatment Outcome	2005
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-20, Volume: 23, Issue:15 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Outcome	2005
Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer. Anti-cancer drugs, 2005, Volume: 16, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epirubicin; Female; Filgrastim; Fluorouracil; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pilot Projects; Polyethylene Glycols; Preoperative Care; Prospective Studies; Receptor, ErbB-2; Recombinant Proteins; Taxoids; Treatment Outcome	2005
HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer, 2005, Jun-01, Volume: 103, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Tumor Suppressor Protein p53	2005
Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Remission Induction; Survival Rate; Taxoids; Treatment Outcome	2005
Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-20, Volume: 23, Issue:15 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Middle Aged; Multigene Family; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; RNA, Neoplasm; Sensitivity and Specificity; Survival Analysis; Taxoids; Treatment Outcome	2005
Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anti-cancer drugs, 2005, Volume: 16, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Glucuronates; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Remission Induction; Taxoids; Treatment Outcome	2005
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-10, Volume: 24, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression Profiling; Humans; Immunohistochemistry; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; NF-kappa B; Prognosis; Taxoids; Treatment Outcome	2006
[Study on efficacy and toxicity of new combined regimen "taxoter + cisplatin + 5-fluorouracil" in disseminated and locally-spread stomach cancer. Comparative analysis of tolerance and efficacy in patients younger and older than 65 years]. Advances in gerontology = Uspekhi gerontologii, 2006, Volume: 18 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Stomach Neoplasms; Taxoids; Treatment Outcome	2006
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer. Cancer, 2006, Aug-15, Volume: 107, Issue:4 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Rate; Taxoids; Treatment Outcome	2006
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 rando Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome	2007
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Polyethylene Glycols; Postmenopause; Premenopause; Preoperative Care; Recombinant Proteins; Taxoids	2007
Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:6 Topics: Age Factors; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Karnofsky Performance Status; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2006
Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:9 Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Risk Factors; Survival Analysis; Taxoids	2006
Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine	2007
A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:2 Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Docetaxel; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Midazolam; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neutropenia; Taxoids	2008
Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer, 2008, Apr-01, Volume: 112, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Case-Control Studies; Cryotherapy; Docetaxel; Evaluation Studies as Topic; Female; Follow-Up Studies; Foot Diseases; Freezing; Humans; Male; Middle Aged; Nail Diseases; Neoplasm Invasiveness; Neoplasms; Onycholysis; Taxoids; Treatment Outcome	2008
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:9 Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Carcinoma, Lobular; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Liver Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation	2008
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. British journal of cancer, 1996, Volume: 74, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors	1996
The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. British journal of clinical pharmacology, 1997, Volume: 43, Issue:6 Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Edema; Female; Flavonoids; Humans; Infusions, Intravenous; Lymphatic System; Middle Aged; Neoplasm Invasiveness; Ovarian Neoplasms; Paclitaxel; Taxoids; Water-Electrolyte Balance	1997

Other Studies

125 other study(ies) available for docetaxel anhydrous and Invasiveness, Neoplasm

Article	Year
Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin. Journal of medicinal chemistry, 2019, 05-23, Volume: 62, Issue:10 Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cell Line, Tumor; Cell Movement; Drug Design; Epithelial-Mesenchymal Transition; Humans; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Structure-Activity Relationship; Triazoles; Xenograft Model Antitumor Assays	2019
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con. European urology focus, 2022, Volume: 8, Issue:4 Topics: BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms	2022
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro. European urology focus, 2022, Volume: 8, Issue:4 Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms	2022
Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study. Urologia internationalis, 2022, Volume: 106, Issue:8 Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Quality of Life; Urinary Bladder Neoplasms	2022
Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer. The Journal of urology, 2022, Volume: 208, Issue:5 Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma in Situ; Docetaxel; Doxorubicin; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms	2022
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer. The Journal of urology, 2022, Volume: 208, Issue:3 Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Carcinoma in Situ; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms	2022
Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer. European urology, 2022, Volume: 82, Issue:6 Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms	2022
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. Urologic oncology, 2023, Volume: 41, Issue:3 Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Docetaxel; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Non-Muscle Invasive Bladder Neoplasms; Retrospective Studies; Salvage Therapy; Urinary Bladder Neoplasms	2023
Nonrisk-adapted Sequential Intravesical Gemcitabine and Docetaxel for Nonmuscle-invasive Bladder Cancer: The Time Is Now. The Journal of urology, 2023, Volume: 210, Issue:1 Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms	2023
Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis. Urologic oncology, 2023, Volume: 41, Issue:9 Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; BCG Vaccine; Cost-Effectiveness Analysis; Docetaxel; Gemcitabine; Humans; Medicare; Neoplasm Invasiveness; Non-Muscle Invasive Bladder Neoplasms; United States; Urinary Bladder Neoplasms	2023
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. The Journal of urology, 2020, Volume: 203, Issue:5 Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Canada; Cystoscopy; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; United States; Urinary Bladder Neoplasms	2020
Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer. Esophagus : official journal of the Japan Esophageal Society, 2020, Volume: 17, Issue:2 Topics: Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Febrile Neutropenia; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vocal Cord Paralysis	2020
Combination of NDRG2 overexpression, X-ray radiation and docetaxel enhances apoptosis and inhibits invasiveness properties of LNCaP cells. Urologic oncology, 2020, Volume: 38, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Tumor Suppressor Proteins; X-Rays	2020
Deficiency of NEIL3 Enhances the Chemotherapy Resistance of Prostate Cancer. International journal of molecular sciences, 2021, Apr-15, Volume: 22, Issue:8 Topics: Androgen Antagonists; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; N-Glycosyl Hydrolases; Neoplasm Invasiveness; Neurosecretory Systems; Prostatic Neoplasms; S Phase	2021
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urologic oncology, 2022, Volume: 40, Issue:1 Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Interferon alpha-2; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms	2022
Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma. Human cell, 2021, Volume: 34, Issue:6 Topics: Aged; Antineoplastic Agents; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Dactinomycin; Depsipeptides; DNA Copy Number Variations; Docetaxel; Drug Screening Assays, Antitumor; Female; Fibrosarcoma; Furans; Humans; Ketones; Neoplasm Invasiveness; Spheroids, Cellular	2021
A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report. Anticancer research, 2017, Volume: 37, Issue:4 Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Remission Induction; Taxoids; Trastuzumab	2017
Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. Cell cycle (Georgetown, Tex.), 2017, Jun-03, Volume: 16, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Proliferation; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Imaging, Three-Dimensional; Leiomyosarcoma; Luminescent Proteins; Mice, Nude; Mice, Transgenic; Neoplasm Invasiveness; Red Fluorescent Protein; Stomach Neoplasms; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays	2017
Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients. British journal of cancer, 2017, Oct-10, Volume: 117, Issue:8 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Docetaxel; Fibroblasts; Fibrosis; Humans; Indoles; Lung Neoplasms; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Transforming Growth Factor beta1	2017
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer. Journal of experimental & clinical cancer research : CR, 2017, Nov-15, Volume: 36, Issue:1 Topics: Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; China; Disease Models, Animal; Docetaxel; Female; Fluorouracil; Humans; Male; Microinjections; Middle Aged; Neoplasm Invasiveness; Neoplasm Transplantation; Pyridines; Stomach Neoplasms; Taxoids; Translational Research, Biomedical; Treatment Outcome; Zebrafish	2017
[Experience with cabazitaxel therapy for patients with metastatic castrate resistant prostate cancer in Hungary]. Magyar onkologia, 2017, Dec-18, Volume: 61, Issue:4 Topics: Age Factors; Aged; Biopsy, Needle; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Hungary; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Patient Safety; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2017
miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer. Cellular signalling, 2018, Volume: 44 Topics: 3' Untranslated Regions; Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Kaempferols; Lymphatic Metastasis; MCF-7 Cells; Microfilament Proteins; MicroRNAs; Neoplasm Invasiveness; Paclitaxel; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Triple Negative Breast Neoplasms	2018
Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer. British journal of cancer, 2018, 03-20, Volume: 118, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Movement; Cell Proliferation; Docetaxel; Drug Synergism; Drugs, Chinese Herbal; Forkhead Box Protein M1; Humans; Lung Neoplasms; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Transcriptome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2018
[Laparoscopic Total Gastrectomy with Pancreatosplenectomy after Neoadjuvant Chemotherapy for Advanced Gastric Cancer with Adjacent Organs Invasion]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Gastrectomy; Humans; Laparoscopy; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatectomy; Splenectomy; Stomach Neoplasms; Taxoids; Tegafur	2017
[Three-Year Survival after Lymphadenectomy for Residual Lymph Node Metastasis of Esophageal Cancer with Invasion into the Trachea and Carotid Artery after Chemoradiotherapy - A Case Report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carotid Arteries; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Neoplasm Invasiveness; Taxoids; Trachea	2017
A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically. Nanomedicine : nanotechnology, biology, and medicine, 2018, Volume: 14, Issue:7 Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Proliferation; Chromones; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Delivery Systems; Drug Therapy, Combination; Esophageal Neoplasms; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Nanomedicine; Neoplasm Invasiveness; Prognosis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2018
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer. Oncology reports, 2018, Volume: 40, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Prostatic Neoplasms; Quinazolines; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2018
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes. Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Retrospective Studies; Survival Rate; Trastuzumab; Young Adult	2019
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma. Thoracic cancer, 2019, Volume: 10, Issue:2 Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Rate; Vinorelbine	2019
Secreted frizzled-related protein 5 suppresses aggressive phenotype and reverses docetaxel resistance in prostate cancer. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2019, Volume: 67, Issue:6 Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; beta Catenin; Carcinogenesis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; G1 Phase; Humans; Male; Mice, Nude; Neoplasm Invasiveness; Phenotype; Prostatic Neoplasms; Resting Phase, Cell Cycle; Signal Transduction	2019
Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization. Cell death & disease, 2019, 02-27, Volume: 10, Issue:3 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Disease Progression; Docetaxel; Female; Gene Knockout Techniques; Heterografts; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Seminal Plasma Proteins	2019
CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely via Induction of Hippo-Yap Signaling. Cells, 2019, 03-30, Volume: 8, Issue:4 Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Docetaxel; Drug Resistance, Neoplasm; Hippo Signaling Pathway; Humans; Hyaluronan Receptors; Male; Neoplasm Invasiveness; Neoplasm Proteins; Phosphoproteins; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Signal Transduction; Transcription Factors; Wound Healing; YAP-Signaling Proteins	2019
AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway. International journal of molecular sciences, 2019, Apr-03, Volume: 20, Issue:7 Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Ribonucleotides; Signal Transduction; TOR Serine-Threonine Kinases; Transforming Growth Factor beta	2019
[Effect of silencing LASP1 on biological behaviors of oral squamous cell carcinoma cells and IC50 of three anti-tumor drugs]. Shanghai kou qiang yi xue = Shanghai journal of stomatology, 2019, Volume: 28, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Docetaxel; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; LIM Domain Proteins; Mice; Mice, Nude; Mouth Neoplasms; Neoplasm Invasiveness	2019
Safety of thoracoscopic esophagectomy after induction chemotherapy for locally advanced unresectable esophageal squamous cell carcinoma. Asian journal of endoscopic surgery, 2020, Volume: 13, Issue:2 Topics: Aged; Antineoplastic Agents; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Feasibility Studies; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Operative Time; Retrospective Studies; Thoracoscopy; Treatment Outcome	2020
Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer research, 2013, Apr-15, Volume: 73, Issue:8 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Docetaxel; Female; Human Umbilical Vein Endothelial Cells; Humans; Matrix Metalloproteinase 14; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Ovarian Neoplasms; Taxoids; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays	2013
Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1. British journal of cancer, 2013, Mar-19, Volume: 108, Issue:5 Topics: Androgen Antagonists; Androgens; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Growth Differentiation Factor 15; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids	2013
[Pathological complete response in a case of advanced esophageal cancer invading aorta treated by preoperative chemotherapy with docetaxel and cisplatin plus 5-FU]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Taxoids	2013
Involvement of miR-20a in promoting gastric cancer progression by targeting early growth response 2 (EGR2). International journal of molecular sciences, 2013, Aug-06, Volume: 14, Issue:8 Topics: Antineoplastic Agents; Carcinogenesis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Early Growth Response Protein 2; Female; Gene Expression; Humans; Male; MicroRNAs; Neoplasm Invasiveness; RNA, Messenger; Stomach Neoplasms; Taxoids	2013
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck. Head & neck, 2014, Volume: 36, Issue:11 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Induction Chemotherapy; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Squamous Cell Carcinoma of Head and Neck; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Outcome	2014
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer. PloS one, 2013, Volume: 8, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygenase 2; Docetaxel; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Nitrobenzenes; Prostatic Neoplasms; Quinazolines; Sulfonamides; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2013
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. European urology, 2014, Volume: 66, Issue:4 Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cohort Studies; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome	2014
Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma. Gastroenterology, 2014, Volume: 146, Issue:7 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cisplatin; Docetaxel; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Eukaryotic Translation Initiation Factor 5A; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Peptide Initiation Factors; Proportional Hazards Models; Protein Binding; RNA Interference; RNA-Binding Proteins; RNA, Messenger; Signal Transduction; Taxoids; Time Factors; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2014
Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. Breast cancer research : BCR, 2014, Mar-19, Volume: 16, Issue:2 Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Docetaxel; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; JNK Mitogen-Activated Protein Kinases; Kaplan-Meier Estimate; Lung Neoplasms; MCF-7 Cells; Microscopy, Fluorescence; Neoplasm Invasiveness; NF-kappa B; Prognosis; Receptor-Interacting Protein Serine-Threonine Kinase 2; RNA Interference; Signal Transduction; Taxoids; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays	2014
A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy. Journal of surgical oncology, 2014, Volume: 109, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Nomograms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; ROC Curve; Survival Rate; Taxoids	2014
Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer. Cell death & disease, 2014, May-08, Volume: 5 Topics: Administration, Metronomic; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Eye Proteins; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Nerve Growth Factors; Prostatic Neoplasms, Castration-Resistant; Serpins; Taxoids; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays	2014
Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-β signalling. Journal of cellular and molecular medicine, 2014, Volume: 18, Issue:12 Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; DNA Methylation; Docetaxel; Dose-Response Relationship, Drug; Epigenesis, Genetic; Eye Proteins; Female; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Stomach Neoplasms; Taxoids; Transcription Factors; Transforming Growth Factor beta; Xenograft Model Antitumor Assays	2014
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma. Annals of surgical oncology, 2015, Volume: 22, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids	2015
Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination. British journal of cancer, 2014, Sep-23, Volume: 111, Issue:7 Topics: Anesthetics, Inhalation; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isoflurane; Male; Neoplasm Invasiveness; Phosphorylation; Propofol; Prostatic Neoplasms; Protein Processing, Post-Translational; Protein Transport; Taxoids; Up-Regulation; Vascular Endothelial Growth Factor A	2014
[A case of gastric cancer with N2 lymph node metastasis and pancreatic invasion effectively treated with docetax-el/S-1 as a neoadjuvant chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pancreas; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome	2014
Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis. The Prostate, 2015, Feb-15, Volume: 75, Issue:3 Topics: Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Humans; Male; Myxovirus Resistance Proteins; Neoplasm Invasiveness; Prostatic Neoplasms; Taxoids; Tubulin	2015
Involvement of FoxQ1 in NSCLC through regulating EMT and increasing chemosensitivity. Oncotarget, 2014, Oct-30, Volume: 5, Issue:20 Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutamates; Guanine; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pemetrexed; RNA, Messenger; Taxoids	2014
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:20 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Retrospective Studies; Risk Assessment; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Turkey; Young Adult	2014
Chemotherapy-Induced miRNA-29c/Catenin-δ Signaling Suppresses Metastasis in Gastric Cancer. Cancer research, 2015, Apr-01, Volume: 75, Issue:7 Topics: Animals; Antineoplastic Agents; Catenins; Cell Line, Tumor; Cell Movement; Cisplatin; Delta Catenin; Docetaxel; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; rho GTP-Binding Proteins; RNA Interference; Stomach Neoplasms; Taxoids	2015
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. Oncotarget, 2015, Jun-20, Volume: 6, Issue:17 Topics: Adenylate Kinase; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Docetaxel; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; Gene Knockdown Techniques; Humans; Male; Metformin; Neoplasm Invasiveness; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Taxoids; Triazoles; Up-Regulation	2015
MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel. Biochemical and biophysical research communications, 2015, Oct-02, Volume: 465, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; MCF-7 Cells; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Receptor, Notch1; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Taxoids	2015
[A Case of Resected Gastric Cancer Invading the Esophagus with Esophageal Recurrence That Responded to Weekly Docetaxel／Cisplatin Chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Esophagus; Gastrectomy; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Recurrence; Stomach Neoplasms; Taxoids; Treatment Outcome	2015
Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2016, Volume: 26, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Taxoids; Uterine Neoplasms	2016
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation. The Korean journal of internal medicine, 2016, Volume: 31, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Docetaxel; Eye; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Medical Records; Middle Aged; Nasal Cavity; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Nose Neoplasms; Organ Sparing Treatments; Paranasal Sinus Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk Factors; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Taxoids; Time Factors; Treatment Outcome; Young Adult	2016
ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases. Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:S3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids	2016
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel to treat synchronous peritoneal carcinomatosis from gastric cancer: Results from a Chinese center. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Cancer, Regional Perfusion; China; Cyclobutanes; Cytoreduction Surgical Procedures; Databases, Factual; Docetaxel; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Organoplatinum Compounds; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Sample Size; Stomach Neoplasms; Taxoids; Treatment Outcome	2016
Functional roles of CSPG4/NG2 in chondrosarcoma. International journal of experimental pathology, 2016, Volume: 97, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Cartilage, Articular; Cell Adhesion; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chondroitin Sulfate Proteoglycans; Chondrosarcoma; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Membrane Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Peptide Hydrolases; RNA, Small Interfering; Taxoids; Young Adult	2016
Blockage of SSRP1/Ets-1/Pim-3 signalling enhances chemosensitivity of nasopharyngeal carcinoma to docetaxel in vitro. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 83 Topics: Autophagy; Carcinoma; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Docetaxel; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; High Mobility Group Proteins; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nasopharynx; Neoplasm Invasiveness; Protein Serine-Threonine Kinases; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins; Signal Transduction; Taxoids; Transcriptional Elongation Factors	2016
Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. Oncotarget, 2016, 09-20, Volume: 7, Issue:38 Topics: Adenocarcinoma; Animals; Apoptosis; bcl-X Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Oncogenes; Phenotype; RNA, Long Noncoding; Taxoids	2016
KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer. Urologic oncology, 2017, Volume: 35, Issue:1 Topics: Aged; Antineoplastic Agents; Blood Vessels; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Hyaluronan Receptors; Kinesins; Male; Neoplasm Grading; Neoplasm Invasiveness; Neoplastic Stem Cells; Prostate; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; RNA, Messenger; RNA, Small Interfering; Spheroids, Cellular; Taxoids	2017
Statin derivatives as therapeutic agents for castration-resistant prostate cancer. Cancer letters, 2016, 12-01, Volume: 383, Issue:1 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholesterol; Docetaxel; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplasm Invasiveness; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Receptors, Androgen; S Phase Cell Cycle Checkpoints; Signal Transduction; Simvastatin; Taxoids	2016
Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface. Oncotarget, 2016, Dec-20, Volume: 7, Issue:51 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Cell Death; Cell Line, Tumor; Cell Membrane; Cell Movement; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Mice, Inbred NOD; Mice, SCID; Neoadjuvant Therapy; Neoplasm Invasiveness; Protein Precursors; Taxoids; Time Factors; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays	2016
MiR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel. Gene, 2017, Feb-05, Volume: 600 Topics: Adaptor Proteins, Vesicular Transport; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; MicroRNAs; Neoplasm Invasiveness; Taxoids; Tumor Stem Cell Assay; Up-Regulation	2017
MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer. Clinical breast cancer, 2017, Volume: 17, Issue:3 Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Female; Follow-Up Studies; Gene Amplification; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Prognosis; Proto-Oncogene Proteins c-myc; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids	2017
Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis. Annals of surgery, 2017, Volume: 265, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Hepatectomy; Humans; Letrozole; Liver Neoplasms; Male; Markov Chains; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Quality-Adjusted Life Years; Survival Rate; Taxoids; Triazoles	2017
Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China. BMC gastroenterology, 2017, Mar-14, Volume: 17, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Cisplatin; Disease-Free Survival; Docetaxel; Drug Combinations; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prognosis; Proportional Hazards Models; Pyridines; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Taxoids; Tegafur; Treatment Outcome; Tumor Burden	2017
The APE1 redox inhibitor E3330 reduces collective cell migration of human breast cancer cells and decreases chemoinvasion and colony formation when combined with docetaxel. Chemical biology & drug design, 2017, Volume: 90, Issue:4 Topics: Antineoplastic Agents; Benzoquinones; Breast; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; DNA-(Apurinic or Apyrimidinic Site) Lyase; Docetaxel; Female; Humans; Neoplasm Invasiveness; Oxidation-Reduction; Propionates; Taxoids	2017
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. European urology, 2009, Volume: 55, Issue:6 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cohort Studies; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Geriatric Assessment; Humans; Infusions, Intravenous; Male; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome	2009
Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Molecular cancer therapeutics, 2008, Volume: 7, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Body Fluids; Cell Line, Tumor; Cell Movement; Disease Progression; Docetaxel; Female; Fibroblasts; Humans; Metalloproteases; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; NIH 3T3 Cells; Oligopeptides; Ovarian Neoplasms; Peritoneum; Receptor, PAR-1; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays	2008
The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience. World journal of urology, 2009, Volume: 27, Issue:3 Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Taxoids; Treatment Failure; Urinary Bladder Neoplasms	2009
Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. International journal of cancer, 2009, Jun-15, Volume: 124, Issue:12 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Chemotaxis; Docetaxel; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Immunoenzyme Techniques; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Phenotype; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Taxoids; Thrombospondin 1; Tumor Cells, Cultured	2009
Evidence of gamma-tocotrienol as an apoptosis-inducing, invasion-suppressing, and chemotherapy drug-sensitizing agent in human melanoma cells. Nutrition and cancer, 2009, Volume: 61, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Cadherins; Cell Line, Tumor; Cell Proliferation; Chromans; Dacarbazine; Docetaxel; Humans; JNK Mitogen-Activated Protein Kinases; Melanoma; Neoplasm Invasiveness; Signal Transduction; Taxoids; Vitamin E	2009
A protein-bound polysaccharide, PSK, enhances tumor suppression induced by docetaxel in a gastric cancer xenograft model. Anticancer research, 2009, Volume: 29, Issue:3 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Docetaxel; Drug Synergism; Electrophoretic Mobility Shift Assay; Female; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Proteoglycans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Survival Rate; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2009
Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget's disease. The British journal of dermatology, 2009, Volume: 161, Issue:3 Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Docetaxel; Female; Fluorouracil; Genital Neoplasms, Male; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paget Disease, Extramammary; Penile Neoplasms; Scrotum; Survival Analysis; Taxoids	2009
Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay. American journal of clinical oncology, 2010, Volume: 33, Issue:4 Topics: Aged; Antineoplastic Agents; Carboplatin; Carcinosarcoma; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Taxoids; Uterine Neoplasms	2010
Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity. BMC cancer, 2010, Jan-14, Volume: 10 Topics: Animals; Antineoplastic Agents; Cell Adhesion; Cell Movement; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Ligands; Male; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Prostatic Neoplasms; Protein Isoforms; Protein Structure, Tertiary; RNA Interference; Taxoids	2010
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells. Molecular cancer therapeutics, 2010, Volume: 9, Issue:3 Topics: Adenocarcinoma; Apoptosis; Cell Fractionation; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Male; Neoplasm Invasiveness; Phosphorylation; Prostate; Prostatic Neoplasms; Quinazolines; Taxoids; Transcription Factors; Veratrum Alkaloids; Zinc Finger Protein GLI1	2010
Docetaxel suppresses invasiveness of head and neck cancer cells in vitro. Cancer science, 2010, Volume: 101, Issue:6 Topics: Antineoplastic Agents, Phytogenic; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Proliferation; Docetaxel; Head and Neck Neoplasms; Humans; Neoplasm Invasiveness; Spheroids, Cellular; Taxoids; Tubulin	2010
The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Annals of surgical oncology, 2010, Volume: 17, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Taxoids; Treatment Outcome; Young Adult	2010
[Safety and tolerance of docetaxel (especially 75 mg/m2) with cyclophosphamide (TC therapy) as adjuvant chemotherapy for Japanese patients with operable breast cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Taxoids	2010
[A case report of bi-weekly docetaxel and S-1 combination chemotherapy for gastric cancer with multiple liver metastases and esophageal invasion]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophagoscopy; Gastroscopy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed	2010
Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology, 2010, Volume: 257, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Contrast Media; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; In Situ Hybridization, Fluorescence; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Prospective Studies; ROC Curve; Statistics, Nonparametric; Taxoids	2010
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer research, 2010, Nov-15, Volume: 70, Issue:22 Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Orchiectomy; Prognosis; Prostate; Prostatectomy; Prostatic Neoplasms; RNA Interference; Survival Analysis; Taxoids; Tubulin	2010
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma. Cancer science, 2011, Volume: 102, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Adhesion; Cell Movement; Cell Proliferation; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2011
[A case of recurrent esophageal cancer with tracheal invasion treated by chemo-radiotherapy (CRT) after placement of tracheal stent that maintained complete response (CR) for two years]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Remission Induction; Stents; Taxoids; Trachea; Tracheal Neoplasms; Tracheal Stenosis	2010
[A case report--locally advanced pancreatic adenocarcinoma was resected after chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12 Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Combinations; Duodenal Neoplasms; Humans; Male; Mesenteric Artery, Superior; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Taxoids; Tegafur	2010
In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-01, Volume: 17, Issue:9 Topics: Adhesiveness; Administration, Intravesical; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Docetaxel; Female; Humans; Mice; Mice, Nude; Mucous Membrane; Muscle, Smooth; Nanoparticles; Neoplasm Invasiveness; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2011
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall. Journal of chemotherapy (Florence, Italy), 2011, Volume: 23, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Docetaxel; Doxorubicin; Female; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Plastic Surgery Procedures; Polyethylene Glycols; Ribs; Taxoids; Thoracic Wall	2011
Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK. Journal of experimental & clinical cancer research : CR, 2011, Jul-29, Volume: 30 Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Therapy, Combination; Female; Glycoproteins; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 3; Neoplasm Invasiveness; Phosphorylation; Real-Time Polymerase Chain Reaction; Receptors, Urokinase Plasminogen Activator; RNA, Messenger; Taxoids; Trypsin Inhibitors; Urokinase-Type Plasminogen Activator	2011
[Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Combinations; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur	2011
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. The Lancet. Oncology, 2012, Volume: 13, Issue:6 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Prostatic Neoplasms; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom	2012
MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Molecular and cellular biochemistry, 2013, Volume: 372, Issue:1-2 Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; Humans; Inhibitory Concentration 50; Lung Neoplasms; Lymphatic Metastasis; MicroRNAs; Neoplasm Invasiveness; PTEN Phosphohydrolase; Radiation Tolerance; RNA Interference; Signal Transduction; Taxoids; Up-Regulation	2013
Radiology quiz case 2. Docetaxel (Taxotere)-induced photosensitivity. Archives of otolaryngology--head & neck surgery, 2012, Volume: 138, Issue:9 Topics: Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Follow-Up Studies; Glottis; Humans; Laryngeal Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Invasiveness; Neoplasm Staging; Parotid Neoplasms; Photosensitivity Disorders; Positron-Emission Tomography; Radiosurgery; Risk Assessment; Taxoids; Tomography, X-Ray Computed; Treatment Outcome	2012
Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer. Acta oto-laryngologica, 2012, Volume: 132, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Radiotherapy, Adjuvant; Risk Assessment; Salvage Therapy; Survival Analysis; Taxoids; Tongue; Tongue Neoplasms; Treatment Outcome	2012
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. The American journal of pathology, 2012, Volume: 181, Issue:6 Topics: Apoptosis; Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Prostatic Neoplasms; Spheroids, Cellular; Taxoids; Tumor Stem Cell Assay; Up-Regulation	2012
Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. The Journal of urology, 2013, Volume: 189, Issue:3 Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome; United States; Urinary Bladder; Urinary Bladder Neoplasms	2013
FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 79, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Proportional Hazards Models; RNA, Messenger; Taxoids; Vinblastine; Vinorelbine	2013
Inhibition of ZEB1 reverses EMT and chemoresistance in docetaxel-resistant human lung adenocarcinoma cell line. Journal of cellular biochemistry, 2013, Volume: 114, Issue:6 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Shape; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; RNA, Small Interfering; Taxoids; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1	2013
Docetaxel-induced nail changes--a neurogenic mechanism: a case report. Journal of neuro-oncology, 2002, Volume: 58, Issue:2 Topics: Afferent Pathways; Arm; Brachial Plexus; Breast Neoplasms; Docetaxel; Efferent Pathways; Female; Humans; Middle Aged; Motor Neurons; Nail Diseases; Neoplasm Invasiveness; Neural Conduction; Neurologic Examination; Neurons, Afferent; Paclitaxel; Paralysis; Parasympathetic Nervous System; Sensory Thresholds; Skin; Sympathetic Nervous System; Taxoids; Vibration	2002
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:9 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Floxuridine; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome	2002
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clinical breast cancer, 2002, Volume: 3, Issue:5 Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Microtubules; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pilot Projects; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Soft Tissue Neoplasms; Survival Analysis; tau Proteins; Taxoids; Treatment Outcome; Tubulin	2002
Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long term results. European urology, 2004, Volume: 46, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Docetaxel; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Remission Induction; Survival Analysis; Taxoids; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms	2004
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncology reports, 2004, Volume: 12, Issue:5 Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid	2004
What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-20, Volume: 23, Issue:15 Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Interprofessional Relations; Male; Medical Oncology; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Care Team; Prognosis; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Urology	2005
[A case of advanced gastric cancer with pulmonary carcinomatous lymphangiosis responding remarkably to combination chemotherapy of docetaxel (TXT) and TS-1]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur	2005
Multiple cutaneous acral metastases in a woman with breast adenocarcinoma treated with pegylated liposomal doxorubicin: incidental or aetiological association? European journal of cancer care, 2005, Volume: 14, Issue:3 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Doxorubicin; Fatal Outcome; Female; Fingers; Humans; Liposomes; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Skin Neoplasms; Taxoids; Toes	2005
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease. Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:12 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome	2003
High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23 Topics: Antineoplastic Agents, Phytogenic; BRCA1 Protein; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Taxoids; Thioredoxins; Tumor Suppressor Protein p53	2005
Clinical experience with docetaxel for Chinese breast cancer patients: hematological toxicity profiles. Breast cancer (Tokyo, Japan), 2006, Volume: 13, Issue:2 Topics: Adult; Aged; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; China; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Immunohistochemistry; Incidence; Mastectomy, Segmental; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids	2006
[A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fever; Gonadotropin-Releasing Hormone; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Prednisolone; Prostatic Neoplasms; Taxoids; Urinary Bladder Neoplasms	2006
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13 Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Taxoids; Vascular Neoplasms	2006
Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. Journal of surgical oncology, 2007, Mar-01, Volume: 95, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Bronchi; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pericardium; Taxoids; Trachea	2007
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Molecular cancer therapeutics, 2007, Volume: 6, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cytochromes c; Docetaxel; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Immunohistochemistry; Male; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quinazolines; Signal Transduction; Taxoids; Tumor Cells, Cultured; Veratrum Alkaloids	2007
Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel. Anti-cancer drugs, 2007, Volume: 18, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Taxoids; Urinary Bladder Neoplasms	2007
Induction chemoradiotherapy prior to surgery for non-small cell lung cancer invading the left atrium. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2008, Volume: 33, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Heart Atria; Heart Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Remission Induction; Taxoids	2008
Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line. Biochimica et biophysica acta, 2008, Volume: 1784, Issue:9 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel; Proteomics; Reactive Oxygen Species; Taxoids	2008
Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. International journal of cancer, 1999, Oct-08, Volume: 83, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Diphosphonates; Docetaxel; Drug Synergism; Humans; Ibandronic Acid; Neoplasm Invasiveness; Paclitaxel; Taxoids; Tumor Cells, Cultured	1999
[A case of advanced breast cancer associated with humoral hypercalcemia that responded to medroxyprogesterone acetate and docetaxel]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:7 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Female; Humans; Hypercalcemia; Lymph Nodes; Lymphatic Metastasis; Medroxyprogesterone Acetate; Neoplasm Invasiveness; Paclitaxel; Taxoids	2000
Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. International journal of cancer, 2002, Jan-01, Volume: 97, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Breast Neoplasms; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA Primers; Docetaxel; Female; Humans; Middle Aged; Mixed Function Oxygenases; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Taxoids	2002
Effects of Taxotere on invasive potential and multidrug resistance phenotype in pancreatic carcinoma cell line SUIT-2. World journal of gastroenterology, 2001, Volume: 7, Issue:1 Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biocompatible Materials; Carcinoma; Collagen; Docetaxel; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorescent Dyes; Humans; In Vitro Techniques; Laminin; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Phenotype; Proteoglycans; Rhodamine 123; RNA, Neoplasm; Taxoids; Tumor Cells, Cultured	2001